
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
Details : RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
Details : RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 24, 2022
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : HLB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)
Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 27, 2022
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : HLB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : HLB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : HLB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259
Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate,Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea
Details : RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and herpes zoster virus, among other pathologies.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Timbetasin Acetate,Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : GT90001 is a fully human monoclonal antibody Activin Receptor-Like Kinase-1, Activin Receptor-Like Kinase-1, inhibits ALK-1/TGF-β signal transduction and tumor angiogenesis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 04, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : ReGenTree
Deal Size : Inapplicable
Deal Type : Inapplicable
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome
Details : The purpose of a pre-BLA meeting is to discuss with FDA the format, content, and acceptability of RGN-259, a sterile, preservative-free eye drop that has been shown to reduce symptoms of dry eye syndrome based on the results to date.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : ReGenTree
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GT90001,KN046
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody (GT90001) in combination with KN046.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : GT90001,KN046
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
